Despite the great potential of human induced pluripotent stem cells (iPSCs), technical and conceptual challenges for disease-specific assay validation often hinder their use during pre-clinical development.Ncardia has established large-scale manufacturing processes for iPSC-derived neuronal sub-populations, microglia and astrocytes and has extensively characterized them using high-content imaging, multi-electrode arrays, flow-cytometry, and transcriptome analysis.
In this webinar, we show validated assays with co-culture of neurons, astrocytes and microglia in multiplexed and sensitive platforms where cell viability, autophagy, mitochondrial function, Ca2+ oscillations, endoplasmic reticulum stress and synaptic function can be perturbed to model neuro-pathological signatures.
These validated platforms provide ideal tools for the screening of novel therapeutic modalities against neurodegenerative pathologies.
The benefits and challenges of iPSC-derived neuronal models
How to describe the CNS pathophysiological changes associated with disease
Optimized assays that recapitulate disease-specific phenotypes